Gert De Meerleer
Show
Sort by
-
A fatal wound complication following sequential anti-angiogenesis, immune checkpoint inhibition and ultra-hypofractionated radiotherapy
-
- Journal Article
- A1
- open access
A trial-based cost-utility analysis of metastasis-directed therapy for oligorecurrent prostate cancer
-
Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial
-
- Conference Paper
- C3
- open access
Four- or 5-weeks of radiotherapy for prostate cancer : interim results of a randomized phase 3 trial
-
- Journal Article
- A1
- open access
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants
-
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
-
- Journal Article
- A1
- open access
Reply to J.-E. Bibault et al, B. Tombal, and C. Cattrini et al
-
4 Weeks versus 5 weeks of hypofractionated high-dose radiation therapy as primary therapy for prostate cancer : interim safety analysis of a randomized phase 3 trial
-
Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence : a prospective, randomized, multicenter phase II trial
-
- Journal Article
- A1
- open access
Combined high dose radiation and pazopanib in metastatic renal cell carcinoma : a phase I dose escalation trial